RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements The Bracelet-1 results have confirmed ONCY's earlier IND213 study results as well as showing that adding an immune checkpoint inhibitor increases disease control in breast cancer patients were heavily pre-treated and in relapse prior to being entered into ONCY's Bracelet-1 Phase 2 trial. So the very good results coming from this trial is another reason why the Bracelet-1 results were selected by ASCO to be presented in an Oral Preentation.